These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20044916)

  • 1. New therapeutic strategies for treatment of neurodegenerative diseases.
    Kazantsev AG
    Curr Pharm Des; 2009; 15(34):3917-8. PubMed ID: 20044916
    [No Abstract]   [Full Text] [Related]  

  • 2. List of drugs in development for neurodegenerative diseases. Update June 2006.
    Kwon MO; Herrling P
    Neurodegener Dis; 2006; 3(3):148-86. PubMed ID: 16954701
    [No Abstract]   [Full Text] [Related]  

  • 3. List of drugs in development for neurodegenerative diseases. Update June 2007.
    Pogacić V; Herrling P
    Neurodegener Dis; 2007; 4(6):443-86. PubMed ID: 17934328
    [No Abstract]   [Full Text] [Related]  

  • 4. List of drugs in development for neurodegenerative diseases. Update September 2005.
    Kwon MO; Herrling P
    Neurodegener Dis; 2005; 2(2):61-108. PubMed ID: 16909049
    [No Abstract]   [Full Text] [Related]  

  • 5. Stimulating the cell's appetite for itself.
    Simonsen A; Stenmark H
    Nat Chem Biol; 2007 Jun; 3(6):304-6. PubMed ID: 17510644
    [No Abstract]   [Full Text] [Related]  

  • 6. Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration.
    Ramos E; Egea J; de Los Ríos C; Marco-Contelles J; Romero A
    Future Med Chem; 2017 May; 9(8):765-780. PubMed ID: 28498717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Studies on Neurodegenerative Diseases and their Treatments.
    Gupta SP
    Curr Top Med Chem; 2020; 20(13):2379. PubMed ID: 32529971
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies.
    Aliev G
    Curr Neuropharmacol; 2019; 17(3):198-200. PubMed ID: 30592253
    [No Abstract]   [Full Text] [Related]  

  • 9. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions.
    Exp Biol Med (Maywood); 2008 Nov; 233(11):vi. PubMed ID: 18957631
    [No Abstract]   [Full Text] [Related]  

  • 10. Conclusive Article: Sorting the Good from the Bad: The Different Approaches to Predict Cognitive Properties of New Symptomatic Drug Candidates for Neurodegenerative Diseases in Early Development.
    Deguil J; Auffret A; Schenker E; Aujard F; Lamberty Y; Bartrès-Faz D; Herrero MT; Blin O; Micallef J; Richardson JC; Bordet R
    CNS Neurol Disord Drug Targets; 2016; 15(7):837-8. PubMed ID: 27549168
    [No Abstract]   [Full Text] [Related]  

  • 11. Multitarget-directed ligands for neurodegenerative diseases: real opportunity or blurry mirage?
    Benchekroun M; Maramai S
    Future Med Chem; 2019 Feb; 11(4):261-263. PubMed ID: 30763133
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
    Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC; Drory VE
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract]   [Full Text] [Related]  

  • 14. List of drugs in development for neurodegenerative diseases. Update June 2004.
    Kwon MO; Fischer F; Matthisson M; Herrling P
    Neurodegener Dis; 2004; 1(2-3):113-52. PubMed ID: 16908983
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial (Thematic Issue: Neuroprotective Effects of Li - It is Elementary).
    Hajek T; Young A
    Curr Alzheimer Res; 2016; 13(8):846-7. PubMed ID: 27040138
    [No Abstract]   [Full Text] [Related]  

  • 16. Flavonoids in the Treatment of Alzheimer's and Other Neurodegenerative Diseases.
    Airoldi C; La Ferla B; D Orazio G; Ciaramelli C; Palmioli A
    Curr Med Chem; 2018; 25(27):3228-3246. PubMed ID: 29424298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emergence of designed multiple ligands for neurodegenerative disorders.
    Geldenhuys WJ; Youdim MB; Carroll RT; Van der Schyf CJ
    Prog Neurobiol; 2011 Sep; 94(4):347-59. PubMed ID: 21536094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases.
    Gontijo VS; Viegas FPD; Ortiz CJC; de Freitas Silva M; Damasio CM; Rosa MC; Campos TG; Couto DS; Tranches Dias KS; Viegas C
    Curr Neuropharmacol; 2020; 18(5):348-407. PubMed ID: 31631821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARs: a new target for neuroprotection.
    Bordet R; Gelé P; Duriez P; Fruchart JC
    J Neurol Neurosurg Psychiatry; 2006 Mar; 77(3):285-7. PubMed ID: 16484630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: "Phytochemicals for Human Diseases: An Update".
    Nabavi SM; Daglia M
    Curr Drug Targets; 2017; 18(13):1467. PubMed ID: 29070008
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.